L11 - PK Variability and TDM

Learning Objectives

• Identify different types of vocabulary in pharmacokinetics (PK).

• Understand how population variability in PK is expressed.

• Describe traditional methods for estimating PK variability and their advantages.

• Discuss population approaches developed to address issues with traditional PK variability estimation.

Variability in Pharmacokinetics

• Sources of Variability:

  • Genetic factors (pharmacogenomics) contribute to variability in drug response.

  • Different medications can interact, influencing drug efficacy and toxicity.

  • Individual responses to the same disease and medication can vary widely:

  • Experiencing toxicity without benefit

  • Achieving therapeutic benefit without toxicity

  • Achieving benefit with zero toxicity

  • No benefit nor toxicity

• Contributing Factors:

  • Drug interactions

  • Genetic variations and organ function (renal and hepatic function)

  • Environmental factors (e.g., smoking, alcoholism)

  • Age-related changes affecting drug metabolism and clearance

Pharmacokinetic Parameters Variation

• Individuals metabolize, distribute, and eliminate drugs differently.

• Important assumption: Plasma concentration is comparable to concentration at drug effect sites for therapeutic efficacy.

  • Some effects (e.g., anticonvulsants) are hard to measure directly; absence of seizures serves as a surrogate endpoint.

Types of Variability

• Inter-individual Variability: Differences among different patients due to varying genetic and health backgrounds.

• Intra-individual Variability: Changes within a single individual, possibly due to dietary factors (e.g., consumption of grapefruit juice) or drug interactions.

• Inter-occasional Variability: Variations due to changes in physical condition, exemplified by digoxin's distribution dynamics before and after exercise.

• Residual Variability: Errors in blood sample measurement due to laboratory factors such as assay sensitivity and storage conditions.

Traditional vs Modern Approaches to PK Estimation

• Traditional Two-Stage Method:

  • Involves full PK analysis for all individuals and averaging results. Requires extensive blood sampling and thus is time-consuming and costly.

  • Mostly applies to healthy volunteers, potentially skewing results for a larger population.

• Mixed-Effects Modeling:

  • Estimates population PK parameters efficiently in a single process using data from many individuals simultaneously.

  • Requires fewer samples from each individual but extensive patient population.

  • It relies on regression analysis to account for fixed and random effects across the population.

Therapeutic Drug Monitoring

• Definition: Adjusting dosing based on drug concentration to achieve effective therapeutic levels while minimizing toxicity.

• Used when:

  • Pharmacological responses are hard to measure.

  • Consequences of inadequate dosing are serious (e.g., immunosuppressants).

  • There is a direct correlation between plasma concentration and clinical effect.

  • Drugs exhibit narrow therapeutic windows (e.g., digoxin, anticonvulsants).

• Process:

• Start with population typical values to estimate an individual dose and measure the blood level.

• Refine estimates based on individual PK characteristics if plasma concentrations deviate from expected values.

Considerations in Drug Concentration Monitoring

• Assessing patient compliance and clinical history before dosage adjustment.

• Need to clarify if the measured drug concentration corresponds to the correct therapeutic range (e.g., trough vs. peak) and biological specimen analyzed (plasma vs. whole blood).

• Adjustments may be necessary based on age, comorbidities, drug interactions, and the patient’s clinical state.

Individualization of Therapy Strategies

• Empirical Dose Adjustment: Particularly for drugs with linear PK behavior.

• Nomograms: Visual aids relating plasma concentration to PK parameters to facilitate calculations for various conditions (e.g., digoxin clearance in congestive heart failure).

• Bayesian Dose Prediction: Utilizes population PK knowledge to suggest dosing based on an individual's current concentration levels, employing computational methods.

Summary and Conclusion

• Identifying variability in patient PK profiles is essential for effective therapeutic drug monitoring and dose individualization.

• Understanding pharmacokinetic principles and patient-specific factors can significantly improve therapeutic outcomes while managing variability effectively.

• Continuous education and adaptation of methodologies in therapeutic drug monitoring practices are key for optimizing patient care in pharmacotherapy.